According to the Financial Times, MSD – known as Merck & Co in the US and Canada – is in the final stages of a $10 billion ...

A new player in radioligand therapies (RLTs), Norway and US-based Actithera, has arrived on the scene with $75.5 million in ...

Whether stemming from early childhood adversity, combat exposure, or interpersonal abuse, trauma leaves long-term imprints on ...

Improving efficiencies and uncomplicating processes are critical to the future success of NHS Trusts across the country. The ...

Taiho Pharmaceutical has suffered a blow to its near-term pipeline after a drug candidate for Duchenne muscular dystrophy ...

Boehringer Ingelheim has raised hopes of a more patient-friendly option with the start of phase 2 testing of BI 1815368, ...

The second annual HLTH Europe conference brought together health leaders, start-ups, investors, and developers from across the globe for a mid-year pulse check on where healthcare innovation stands ...

A new formulation of Novartis' antimalarial Coartem has become the first medicine to be approved for use in very young ...